Healthcare has progressed rapidly in recent years, thanks to the latest technological innovations. New cancer therapies are being developed at a rapid pace, and Bristol-based CytoSeek is one such startup. It’s a discovery stage biotech developing the next generation of cell therapies to treat cancer due to solid tumours.
The biotech startup has now bagged £3.5 million seed funding to accelerate the commercialisation of its Artificial Membrane Binding Protein (AMPB) technology, which will be used to discover the potential of immune cell therapies for treating solid tumours. The funding round was led by the newly established deep tech fund Science Creates Ventures (SCV). This firm includes a syndicate composed of Parkwalk, Melltwind, Luminous Ventures, UKI2S and angels.
Founded in 2017 by Professor Adam Perriman, CytoSeek is a University of Bristol spin-out that is currently led by experienced biotech CEO Dr Carolyn Porter. In a conversation with UKTN, Porter tells us more about the startup, the innovations it’s working upon and more. ...